These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8083718)

  • 1. Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study.
    Sadowitz PD; Dubowy R; Souid A; Pollock BH; Weinstein H; Parmley RT; Bowman WP; Land V; Vats T; Pratt C
    J Clin Oncol; 1994 Sep; 12(9):1969-73. PubMed ID: 8083718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology.
    Pein F; Tournade MF; Zucker JM; Brunat-Mentigny M; Deville A; Boutard P; Dusol F; Gentet JC; Legall E; Mechinaud F
    J Clin Oncol; 1994 May; 12(5):931-6. PubMed ID: 8164044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
    Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
    Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
    Letendre L; Noel P; Tefferi A; Solberg LA; Gastineau DA; Hoagland HC
    Am J Clin Oncol; 1995 Oct; 18(5):382-4. PubMed ID: 7572751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
    Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
    J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
    Nichols CR; Andersen J; Lazarus HM; Fisher H; Greer J; Stadtmauer EA; Loehrer PJ; Trump DL
    J Clin Oncol; 1992 Apr; 10(4):558-63. PubMed ID: 1312584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Letendre L; Kottke TJ; Safgren S; Greer J; Gojo I; Atherton P; Svingen PA; Loegering DA; Litzow MR; Sloan JA; Reid JM; Ames MM; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Sep; 11(18):6641-9. PubMed ID: 16166443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experiences with the combination carboplatin/VP 16 in the treatment of recurrent tumors in children].
    Calaminus G; Jürgens H; Schwamborn D; Janssen G; Göbel U
    Klin Padiatr; 1989; 201(4):311-5. PubMed ID: 2674535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose carboplatin in the treatment of hematologic malignancies.
    Vogler WR
    Oncology; 1993 Nov; 50 Suppl 2():42-6. PubMed ID: 8233301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study.
    Frappaz D; Michon J; Hartmann O; Bouffet E; Lejars O; Rubie H; Gentet JC; Chastagner P; Sariban E; Brugiere L
    J Clin Oncol; 1992 Oct; 10(10):1592-601. PubMed ID: 1403039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
    Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
    Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
    Montefusco E; Petti MC; Alimena G; Latagliata R; Celesti F; Capria S; Amadori S; Avvisati G; Mandelli F
    Ann Oncol; 1997 Feb; 8(2):175-9. PubMed ID: 9093727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
    Marina NM; Rodman J; Shema SJ; Bowman LC; Douglass E; Furman W; Santana VM; Hudson M; Wilimas J; Meyer W
    J Clin Oncol; 1993 Mar; 11(3):554-60. PubMed ID: 8445431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.